Ruxolitinib
Orphan DrugFDA Approved
Contents
Description
Ruxolitinib is a selective JAK1/JAK2 inhibitor approved for steroid-refractory acute and chronic graft-versus-host disease. It modulates inflammatory cytokine signaling that drives GVHD pathology. The drug has shown efficacy in both adult and pediatric patients with inadequate response to corticosteroids.
Indications & Therapeutic Use
acute graft-versus-host disease, chronic graft-versus-host disease, myelofibrosis, polycythemia vera
Global Availability (11 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Ruxolitinib — GNH India
35 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
JAKAFI
10mgtabletUSA
Jakavi
EU
Jakavi 10 mg
10mgtabletSwitzerland
Jakavi 20mg
20mg
Jakavi 5 mg
5mgtabletIndia
Opzelura
1.5% x 100gmcreamGermany
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Ruxolitinib
| Generic Name | ruxolitinib |
| Brands | 1 brand available |
| Active Ingredient | ruxolitinib phosphate |
| Drug Class | acute graft-versus-host disease |
| Manufacturer | Incyte Corporation |
| Dosage Forms | Oral tablet, 5mg, 10mg, 15mg, 20mg, 25mg; Topical cream 1.5% |
| Medical Code | L01EJ01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00934544 |
| Countries | 11 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations12 Validated Nodes